Dr. Matthew P. Gilbert, DO, MPH
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 227
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
VT license 032.0052485
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Univ. of Vermont - Fletcher Allen Health Care Burlington, VT
- The University of Vermont Health Network - Champl Plattsburgh, NY
- Northwestern Medical Center Inc Saint Albans, VT
- Porter Hospital Inc Middlebury, VT
- Elizabethtown Community Hospital Elizabethtown, NY
Medical groups
- University of Vermont Medical Center Inc (1,208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 227
- Services billed
- 422
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 186 | 140 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 89 | 42 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 52 | 32 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 35 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in South Burlington, VT | 222 |
| Ozempic (semaglutide) Other prescribers in South Burlington, VT | 131 |
| Trulicity (dulaglutide) Other prescribers in South Burlington, VT | 114 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in South Burlington, VT | 95 |
| Jardiance (empagliflozin) Other prescribers in South Burlington, VT | 84 |
| Synthroid (levothyroxine sodium) Other prescribers in South Burlington, VT | 55 |
| Humalog Kwikpen U-100 (insulin lispro) Other prescribers in South Burlington, VT | 45 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in South Burlington, VT | 41 |
| Novolog Flexpen (insulin aspart) Other prescribers in South Burlington, VT | 39 |
| Metformin Hcl Other prescribers in South Burlington, VT | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 15 payments worth $15,341 in total to this clinician.
| Novo Nordisk Inc | $15,341 |
|---|
| Consulting Fee | $12,904 |
|---|---|
| Travel and Lodging | $1,662 |
| Food and Beverage | $550 |
| Education | $226 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Apr 23, 2025 | Consulting Fee Ozempic · Diabetes | $9,184 |
| Novo Nordisk Inc Aug 14, 2025 | Consulting Fee Rybelsus · Diabetes | $1,395 |
| Novo Nordisk Inc Aug 13, 2025 | Consulting Fee Rybelsus · Diabetes | $1,395 |
| Novo Nordisk Inc Apr 22, 2025 | Consulting Fee Ozempic · Diabetes | $930 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $701 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $608 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $353 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Aug 14, 2025 | Consulting Fee Rybelsus · Diabetes | $1,395 |
| Novo Nordisk Inc Aug 13, 2025 | Consulting Fee Rybelsus · Diabetes | $1,395 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc May 2, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc Apr 23, 2025 | Consulting Fee Ozempic · Diabetes | $9,184 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $701 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $608 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $353 |
| Novo Nordisk Inc Apr 22, 2025 | Consulting Fee Ozempic · Diabetes | $930 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $48,850 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.